Filing Analysis
Securities Offering
Filed Apr 03, 2026
MEDIUM
Entera Bio Ltd. entered into a $10 million private placement agreement with BVF Partners LP to fund its Phase 3 clinical trial for EB613. The offering involves the issuance of units consisting of ordinary shares (or pre-funded warrants) and warrants to purchase additional shares.
Red Flags
- Significant potential dilution: Each unit carries 1.5 warrants, meaning the warrant coverage is 150%.
- Concentrated ownership: The investor (BVF Partners) has beneficial ownership caps set at 19.99%, indicating a major stake in the company.
Key Facts
- Agreement signed on April 1, 2026, with closing on April 2, 2026.
- The company issued 7,827,789 units at a price of $1.2775 per unit.
- Total gross proceeds from the private placement are approximately $10.0 million.
- Each unit includes one ordinary share (or pre-funded warrant) and a warrant to purchase 1.5 ordinary shares.
- The ordinary share warrants have an exercise price of $1.24 and a five-year term.
- If all warrants are exercised for cash, the company would receive an additional $14.5 million.
- Proceeds are designated for the Phase 3 registrational study of EB613 in postmenopausal women with osteoporosis.
Regulation FD Disclosure
Filed Mar 27, 2026
LOW
Entera Bio Ltd. announced its financial results for the fiscal year ended December 31, 2025, and provided business updates. The information was furnished via a press release on March 27, 2026.
Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
- The report was signed by CEO Miranda Toledano on March 27, 2026.
- The company is an Israeli-based entity with ordinary shares and warrants listed on the Nasdaq Capital Market.
Regulation FD Disclosure
Filed Mar 04, 2026
LOW
Entera Bio Ltd. announced the submission of its Phase 3 clinical trial protocol to the FDA for EB613, targeting postmenopausal women with osteoporosis. This submission marks a significant regulatory milestone as the company prepares to initiate a registrational trial.
Key Facts
- Submitted Phase 3 protocol for EB613 to the FDA on March 4, 2026.
- The trial targets postmenopausal women with osteoporosis.
- The disclosure was made via a press release furnished under Item 7.01 Regulation FD.
- EB613 is the company's lead oral PTH (1-34) candidate.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.